NCT05327270View on ClinicalTrials.gov

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions

Head and Neck Cancer

Interventions

DRUG

Nivolumab

Given by IT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER